<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YPXR733M/cf1d688c-cf40-48c6-8fe1-01586c2e47d9/PDF"><dcterms:extent>700 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-YPXR733M/8777a623-4513-482a-8059-780c2d5cd9f8/TEXT"><dcterms:extent>28 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-YPXR733M"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2025</dcterms:issued><dc:creator>Čuš, Tilen</dc:creator><dc:creator>Kočevar Glavač, Nina</dc:creator><dc:creator>Mravljak, Janez</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:76</dc:format><dc:format xml:lang="sl">str. 22-29</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID_HOST:230961923</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-YPXR733M</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">fukoziltransferaze</dc:subject><dc:subject xml:lang="sl">glikozilacija</dc:subject><dc:subject xml:lang="sl">Metastaziranje</dc:subject><dc:subject xml:lang="sl">Rak (medicina)</dc:subject><dc:subject xml:lang="sl">sialiltransferaze</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Vloga fukozil- in sialiltransferaz pri rakavih obolenjih in procesu metastaziranja| The role of fucosyl- and sialyltransferases in cancer and metastasis|</dc:title><dc:description xml:lang="sl">Cancer is one of the leading causes of mortality in the developed world, with 90% of cancer-related deaths being associated with metastasis. This is a complex process involving numerous biochemical changes, including alterations in cellular glycosylation – particularly sialylation and fucosylation. In this process, sialyl- and fucosyltransferases are central enzymes that catalyze the attachment of sialic acid and fucose to their corresponding substrates. Changes in their expression can be observed in various cancers, where they may lead to alterations in cell adhesion, proliferation, motility, tumor angiogenesis, and immune system evasion, significantly enhancing the metastatic potential of cancer cells. Additionally, their increased activity is linked to various types of cancer, such as breast, colon, and pancreatic cancers. Understanding their role in both physiological and pathological conditions offers new possibilities for innovative approaches in cancer treatment and diagnosis,</dc:description><dc:description xml:lang="sl">Rakave bolezni so eden izmed vodilnih vzrokov umrljivosti v razvitem svetu, pri čemer je 90 % smrti bolnikov z rakom povezanih z metastaziranjem. gre za zapleten proces, ki vključuje številne biokemične spremembe, med katerimi so pogoste tudi spremembe v celični glikozilaciji, zlasti sializaciji ter fukozilaciji. Ključno vlogo pri tem igrajo encimi sialil- in fukoziltransferaze, ki katalizirajo vezavo sialične kisline in fukoze na ustrezne substrate. Spremembe v njihovem izražanju opazimo pri številnih rakih, kjer lahko pripeljejo do sprememb v adheziji celic, proliferaciji, gibljivosti, ožiljenosti tumorja in izogibanju rakavih celic pred imunskim sistemom, kar lahko pomembno ojača metastatski potencial rakavih celic. hkrati je povišana aktivnost sialil- in fukoziltransferaz povezana s številnimi rakavimi boleznimi, kot so rak dojk, debelega črevesja in pankreasa. Razumevanje njihove vloge v fizioloških in patofizioloških stanjih tako ponuja nove možnosti v zdravljenju in diagnostiki</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-YPXR733M"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-YPXR733M" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-YPXR733M/cf1d688c-cf40-48c6-8fe1-01586c2e47d9/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-YPXR733M/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-YPXR733M" /></ore:Aggregation></rdf:RDF>